Abstract
Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Current Drug Therapy
Title:Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study
Volume: 8 Issue: 3
Author(s): Philippe Bareille, Ann Allen, Kelly Hardes and Alison Donald
Affiliation:
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Abstract: Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Export Options
About this article
Cite this article as:
Bareille Philippe, Allen Ann, Hardes Kelly and Donald Alison, Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113089990005
DOI https://dx.doi.org/10.2174/15748855113089990005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Molecular Functions of Nod Proteins and their Associated Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Characterization, ACE Inhibitory and Antioxidative Properties of Peptide Fractions Obtained from White Shrimp (<i>Litopenaeus vannamei</i>)
Current Bioactive Compounds Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?
Current Drug Safety G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design Episcleritis and Scleritis in Rheumatic Disease
Current Rheumatology Reviews Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Early Life Vitamin D Status and Lung Development
Current Respiratory Medicine Reviews Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal Editorial: The Diagnosis and Management of Asthma: Are We Moving in the Right Direction?
Current Respiratory Medicine Reviews Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Propranolol Safety Profile in Children
Current Drug Safety The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews An Overview of Different Analytical Techniques for Leukotriene Antagonists in Different Matrices
Current Pharmaceutical Analysis Underexpression of miR-486-5p but not Overexpression of miR-155 is Associated with Lung Cancer Stages
MicroRNA Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Basophil Activation Test with Indomethacin to Assess Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs: A Preliminary Study
Inflammation & Allergy - Drug Targets (Discontinued)